论文部分内容阅读
目的探讨金水宝胶囊联合复方α-酮酸片治疗慢性肾功能衰竭的临床疗效。方法选取2012年3月—2016年3月在宝鸡市第二人民医院接受治疗的慢性肾功能衰竭患者196例,随机分为对照组(98例)和治疗组(98例)。所有患者均给予常规治疗。对照组口服复方α-酮酸片,4片/次,3次/d。治疗组在对照组的基础上口服金水宝胶囊,3粒/次,3次/d。两组患者均连续治疗2个月。比较两组临床疗效,内生肌酐清除率(Ccr)、血肌酐(Scr)、血清尿素氮(BUN)、转化生长因子-β1(TGF-β1)和Ⅳ型胶原蛋白(IV-C)。结果治疗后,对照组和治疗组总有效率分别为83.67%和94.90%,两组比较差异有统计学意义(P<0.05)。治疗后,两组Scr、BUN水平均较同组治疗前显著降低,Ccr水平则升高,同组治疗前后差异具有统计学意义(P<0.05);且治疗后,治疗组这些观察指标显著优于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组TGF-β1和IV-C水平均低于同组治疗前,同组治疗前后差异具有统计学意义(P<0.05);且治疗后,治疗组TGF-β1、IV-C水平显著低于对照组,两组比较差异具有统计学意义(P<0.05)。结论金水宝胶囊联合复方α-酮酸片治疗慢性肾功能衰竭具有显著的疗效,可明显改善患者肾功能,降低尿TGF-β1和IV-C水平,具有一定的临床推广应用价值。
Objective To investigate the clinical efficacy of Jinshuibao capsule combined with a-ketoacid tablets in the treatment of chronic renal failure. Methods A total of 196 patients with chronic renal failure treated in Baoji Second People ’s Hospital from March 2012 to March 2016 were randomly divided into control group (98 cases) and treatment group (98 cases). All patients were given routine treatment. The control group oral compound α-ketoacid tablets, 4 tablets / time, 3 times / d. Treatment group on the basis of the control group oral Jinshuobao capsules, 3 capsules / time, 3 times / d. Two groups of patients were treated for 2 months. The clinical efficacy, Ccr, Scr, BUN, TGF-β1 and IV-C were compared between the two groups. Results After treatment, the total effective rate of the control group and the treatment group were 83.67% and 94.90%, respectively, with significant difference between the two groups (P <0.05). After treatment, the levels of Scr and BUN in both groups were significantly lower than those before treatment and the levels of Ccr were increased in the two groups (P <0.05). After treatment, the indexes in the treatment group were significantly better In the control group, the difference between the two groups was statistically significant (P <0.05). After treatment, the levels of TGF-β1 and IV-C in both groups were significantly lower than those in the same group before and after treatment (P <0.05). After treatment, the levels of TGF-β1 and IV-C Significantly lower than the control group, the difference between the two groups was statistically significant (P <0.05). Conclusions Jinshuibao capsule combined with compound α-ketoacid tablets has a significant therapeutic effect on chronic renal failure, which can significantly improve renal function and reduce the levels of urinary TGF-β1 and IV-C in urine. It has certain clinical application value.